CytoDyn announced a CytoDyn CEO transition on October 19, 2026, appointing Robert E. Hoffman to succeed Dr. Jacob Lalezari effective October 20. Hoffman will retain his principal accounting officer duties, while Lalezari will remain with the biotechnology company as Head of Research and Translational Sciences.
Key Takeaways
- Hoffman moves from chief financial officer to CEO, retaining his principal accounting officer role.
- Lalezari stays with CytoDyn in a non-executive research position focused on leronlimab.
- The board approved higher compensation for Hoffman, including options to purchase 2.5 million shares.
Table of Contents
- CytoDyn CEO transition keeps both leaders at the company
- New compensation includes a multiyear option award
- Lalezari shifts his attention to oncology research
- Conclusion
CytoDyn CEO transition keeps both leaders at the company
CytoDyn’s board approved Hoffman’s appointment on October 16, following discussions involving its Nominating and Corporate Governance Committee and Lalezari. The public announcement followed on October 19, ahead of the October 20 effective date.
The company’s leadership transition filing confirms that Lalezari accepted a non-executive research role rather than leaving the business. He had served as CEO since November 2023.
Hoffman joined CytoDyn as chief financial officer on May 15, 2025. His previous biotechnology roles include president and CEO of Kintara Therapeutics and chief financial officer positions at Heron Therapeutics and AnaptysBio. The appointment puts an executive with both financial and operating leadership experience in charge.
| Item | Details |
|---|---|
| Hoffman’s annual base salary | $525,000. |
| Bonus target | Raised from 40% to 50%. |
| Stock-option award | Options to purchase 2,500,000 shares. |
| Option vesting | 25% on October 16, 2027; the balance in equal monthly installments through October 16, 2030. |
| Option expiration | October 16, 2036. |
New compensation includes a multiyear option award
The board’s Compensation Committee approved changes to Hoffman’s compensation for the fiscal year ending May 31, 2027, effective with his promotion. The package combines a higher annual salary and bonus target with a stock-option award that vests over four years.
The option exercise price will equal the higher of CytoDyn’s closing share prices on October 16 and October 20, 2026. That formula does not establish a fixed exercise price in advance of the second trading date. Lalezari’s compensation was unchanged under his replacement employment agreement.
Lalezari shifts his attention to oncology research
Lalezari’s new responsibilities center on identifying and advancing opportunities for leronlimab in solid-tumor oncology. Leronlimab is a humanized monoclonal antibody targeting the CCR5 receptor and remains in clinical development.
The transition separates executive leadership from Lalezari’s research responsibilities while keeping him involved in the company’s drug-development work. The appointment itself is a governance change, not evidence of a clinical result or regulatory approval.
Conclusion
The next confirmed step is the October 20, 2026 handover, when Hoffman assumes the CEO role and Lalezari moves into his research position. That date also determines the second share price used to set Hoffman’s option exercise price.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
